A New Pill Nearly Doubles Survival in Advanced Pancreatic Cancer: Inside the RASolute 302 Trial

Every so often in oncology, a trial result comes along that genuinely changes how we talk to patients about what is possible. For metastatic pancreatic cancer — a disease where, historically, doubling survival from six months to seven has counted as a win — the results of the Phase 3 RASolute 302 trial, published this year and presented at the 2026 ASCO Annual Meeting, are the kind of result that makes me want to tell every patient facing this diagnosis.

The drug being tested is daraxonrasib, an oral medication that targets a family of proteins called RAS. If you have read anything I have written about pancreatic cancer biology, you know that RAS mutations — particularly in the KRAS gene — drive the overwhelming majority of pancreatic ductal adenocarcinomas. For years, RAS was considered "undruggable": its structure made it extraordinarily difficult to design a molecule that could block it effectively. Daraxonrasib is part of a new generation of RAS inhibitors designed to overcome that problem, and unlike some earlier RAS-targeted drugs that only worked against one specific mutation, daraxonrasib was tested in patients regardless of their exact RAS mutation status — including the common G12D, G12V, and G12R variants, as well as tumors with wild-type (non-mutated) RAS.

RASolute 302 was a global, randomized Phase 3 trial that enrolled adults with metastatic pancreatic ductal adenocarcinoma whose disease had already progressed after prior treatment — this was a second-line setting, patients who had already been through standard chemotherapy. Participants were randomized to receive daraxonrasib, taken orally once daily at 300 mg, or the physician's choice of standard intravenous chemotherapy.

The results were striking. Median overall survival was 13.2 months with daraxonrasib, compared to 6.7 months with chemotherapy — very close to doubling survival time, with a hazard ratio of 0.40 (meaning the risk of death was reduced by roughly 60 percent) and a highly statistically significant p-value below .0001. Dr. Brian Wolpin of Dana-Farber Cancer Institute, one of the investigators, described it as "a clear and highly meaningful step forward for patients with pancreatic cancer who have experienced progression on prior treatment" — and I do not think that is an overstatement.

What makes this trial particularly important to me as a clinician is not just the size of the benefit, but the fact that it applied broadly across patients with different RAS mutation profiles, rather than being restricted to a narrow molecular subgroup. Most of my patients with pancreatic cancer do not know their exact RAS mutation status when we first discuss treatment options, and a drug that does not require razor-precise molecular matching is far easier to deploy in real-world practice.

The results have been submitted as part of a new drug application to the FDA, so daraxonrasib is not yet available outside of clinical trials as of this writing. That matters for how I counsel patients today: if you or a family member has metastatic pancreatic cancer that has progressed after first-line chemotherapy, this is exactly the kind of result that should prompt a conversation with your oncologist about whether you are eligible for a clinical trial involving daraxonrasib, or what the anticipated timeline for approval might look like, since regulatory review can move quickly for drugs showing this magnitude of benefit in a disease with such limited options.

I also want to place this in context. An improvement from roughly seven months to thirteen months of median survival is enormous in the world of pancreatic cancer, but it is not a cure, and most patients on this trial still eventually experienced disease progression. What this result does represent is real, meaningful additional time — time that, in my experience, patients and families use in ways that matter deeply to them, whether that is attending a milestone event, completing a course of a less toxic treatment, or simply having more good days.

Pancreatic cancer research has been frustratingly slow for decades, largely because the biology of this tumor is so resistant to the therapies that have transformed other cancers. Results like RASolute 302 are the reason I remain genuinely optimistic that the tide is beginning to turn, particularly as several other RAS-targeted agents are now moving through earlier-phase trials behind daraxonrasib.

Source: RASolute 302 Phase 3 trial (Revolution Medicines), published April 2026; presented at the 2026 ASCO Annual Meeting.